Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors
The immunotherapeutic catumaxomab targets EpCAM positive cancers and is approved for the treatment of peritoneal carcinomatosis. To assess the safety of intravenous applications a phase 1 clinical trial was initiated. Treatment of EpCAM positive tumor patients with catumaxomab caused dose dependent...
Main Authors: | , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053709/ |